MIRACL


Also found in: Acronyms, Wikipedia.
Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering Cardiology. A trial that asked whether early, rapid and profound cholesterol-lowering therapy with atorvastatin reduces early recurrent ischaemic events in patients with unstable angina or non-Q-wave MI
Conclusion A primary endpoint of major acute coronary events (MACE) occurred in 14.8% of atorvastatin patients and 17.4% of placebo patients (p = 0.05). Atorvastatin reduced the risk of ischaemia (6.2% vs. 8.4%; p = 0.02), but did not reduce the risk of MACE. Stroke occurred in 12 atorvastatin patients and 24 placebo patients (p = 0.04)

MIRACL

Cardiology A clinical trial–Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering
Mentioned in ?
References in periodicals archive ?
Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
Moreover, that trial has been convincingly supported by the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) trial.
Moreover, that trial has been convincingly supported by a second study, the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) trial.
Take the miracl e of our age, Sir Philip Sidney." (15) As Andrea McRea notes, by the late 1590s "Sidney was on the way to being remembered less as a courtier devoted to serving the state at home and the Protestant cause abroad than the influential and popular poet he was to become." (16) By the early 1600s, the transformation from a military-literary figure to a nearly exclusively literary one was complete.
In the fall of 1997, the Clinton administration allowed the testing of the US Army's mid-infrared advanced chemical laser (MIRACL) against an orbiting Air Force satellite, the stated objective of which involved collecting "data that will help us improve computer models used in planning protection measures for U.S.
Washington's October 1997 test of the Mid-Infrared Chemical Laser (MIRACL), developed under President Reagan's Strategic Defense Initiative, against a dying U.S.
The GTI-funded project tested the use of two chemical lasers, the Army's Mid-InfraRed Advanced Chemical Laser (MIRACL) and the Air Force's Chemical Oxygen Iodine Laser (COIL); and one gas laser, the Air Force's CO2 laser.
During the 1980s, through the Mid Infra-Red Advanced Chemical Laser (MIRACL) program, the state of the art has advanced to the point where today there are a host of possible military (and civilian) applications.
The American Gas Research Institute in Chicago has created a powerful Mid Infrared Advanced Chemical Laser (MIRACL), capable of unleashing a two million watt beam for over five seconds.
Other studies examining aggressive lipid lowering with LIPITOR in more than 40,000 patients include the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial, Stroke Prevention with Aggressive Reduction of Cholesterol Lowering (SPARCL) trial, and the REVERSAL trial examining atherosclerotic regression with aggressive LDL-C reduction.
It may not be Pulitzer material, but it's interesting to know that the MIRACL laser (a proto-Star Wars weapon) costs more to run per second than the entire federal government; that as many as six officials may have access to the code that would launch a nuclear strike; that a man named Francis Dellenbach is living in an abandoned missile silo and has painted its doors (which leak) hot pink.